Desempenho do escore prognóstico de Glasgow no câncer gástrico
DOI:
https://doi.org/10.11606/issn.2176-7262.rmrp.2021.174590Palavras-chave:
Neoplasias Gástricas, Escala de Resultado de Glasgow, Revisão Sistemática, Metanálise, Sobrevida, Complicações pós-operatóriasResumo
A resposta inflamatória sistêmica e o déficit nutricional são características frequentes nos pacientes com câncer e o escore prognóstico de Glasgow tem se mostrado excelente valor prognóstico no câncer gastresofágico e ferramenta validada na avaliação clínica de pacientes com câncer. Assim, o presente estudo teve como objetivo analisar a associação do escore prognóstico de Glasgow com sobrevida de pacientes portadores de carcinoma gástrico, através de revisão sistemática e meta-análise. Foi seguida a metodologia Preferred Reporting Items for Systematic Reviews and Meta-Analyses-PRISMA, com pesquisa nas plataformas Medline, Web of Science e SCOPUS, utilizando descritores apropriados. Foram incluídos estudos clínicos e observacionais, publicados antes de 30.09.2017 e sem restrição de linguagem. Os critérios de inclusão foram a utilização do escore prognóstico de Glasgow como fator prognóstico em pacientes portadores de diagnóstico histológico de carcinoma gástrico; com idade superior a 18 anos; submetidos à quimioterapia, radioterapia ou cirurgia; com dosagem de Proteína C Reativa e albumina no pré-tratamento; e com dados referentes à sobrevida durante o estudo. A qualidade dos estudos foi avaliada com a Escala de Newcastle-Ottawa e o risco de viés com ferramenta da Cochrane Collaboration. Hazard-Ratio e Intervalo de Confiança de 95% foram extraídos dos estudos, e a significância estatística definida como p<0,05. Foram identificados 255 artigos, e por fim, analisados 15 estudos. A análise apresentou o escore prognóstico de Glasgow como fator de risco relacionado à sobrevida e considerado marcador prognóstico independente quando relacionado à sobrevida global dos pacientes com câncer gástrico que realizaram cirurgia e quimioterapia.
Downloads
Referências
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. Doi: 10.3322/caac.20107.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E86.
INCA. Instituto do Câncer. Estimativa. Incidência de câncer no Brasil. Rio de Janeiro: Instituto do Cancer; 2008.
Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1204-12.
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-99. Doi: 10.1016/j.cell.2010.01.025
Leuenberger Ml, Kurmann S, Stanga Z. Nutritional screening tools in daily clinical practice: the focus on cancer. Support Care Cancer. 2010;18 Suppl 2:S17-S27. Doi:10.1007/s00520-009-0805-1.
Kim KH, Park DJ, Park YS, Ahn SH, Park DJ, Kim HH. Actual 5-Year Nutritional Outcomes of Patients with Gastric Cancer. J Gastric Cancer. 2017;17(2):99-109.
Gnagnarella P. Nutrition and cancer: from prevention to nutritional support, 8th October 2010, Milan. Ecancermedicalscience. 2010;4:1-26. Doi: 10.3332/ecancer.2010.205.
Sun K, Chen S, Xu J, Li G, He Y. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140(9):1537-49. Doi: 10.1007/s00432-014-1714-3.
Schwegler I, von Holzen A, Gutzwiller J-P, Schlumpf R, Mühlebach S, Stanga Z. Nutritional risk is a clinical predictor of postoperative mortality and morbidity in surgery for colorectal cancer. British J Surg. 2009;97(1):92-7. Doi: 10.1002/bjs.6805.
McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534-40. Doi: 10.1016/j.ctrv.201.08.003.
Ahmad J, Grimes N, Farid S, Morris-Stiff G. Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review. Hepatobiliary Pancreatic Dis Int. 2014;13(5):474-81. Doi: 10.1016/s1499-3872(14)60284-8.
Heys SD, Walker LG, Deehan DJ, Eremin OE. Serum albumin: a prognostic indicator in patients with colorectal cancer. J R Coll Surg Edinb. 1998;43(3):163-8.
Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutrition J. 2010;9(1):69.
Wei X-l, Wang F-h, Zhang D-s, Qiu M-z, Ren C, Jin Y, et al. A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio. BMC Cancer. 2015;15(1):1-11.
Chen Z, Shao Y, Fan M, Zhuang Q, Wang K, Cao W, et al. Prognostic significance of preoperative C-reactive protein: albumin ratio in patients with clear cell renal cell carcinoma. Int J Clin Exp Pathol. 2015;8(11):14893-900.
Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, et al. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2014;22(3):803-10.
Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89(6):1028-30.
Quyen TC, Angkatavanich J, Thuan TV, Xuan VV, Tuyen LD, Tu DA. Nutrition assessment and its relationship with performance and Glasgow prognostic scores in Vietnamese patients with esophageal cancer. Asia Pac J Clin Nutr. 2017;26(1):49-58.
Maurício SF, da Silva JB, Bering T, Correia MITD. Relationship between nutritional status and the Glasgow Prognostic Score in patients with colorectal cancer. Nutrition. 2013;29(4):625-9.
Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DSJ, Foulis AK, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104(4):726-34.
Saijo M, Nakamura K, Masuyama H, Ida N, Haruma T, Kusumoto T, et al. Glasgow prognostic score is a prognosis predictor for patients with endometrial cancer. Eur J Obstet Gynecol Reprod Biol. 2017;210:355-9.
Sharma R, Hook J, Kumar M, Gabra H. Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur J Cancer. 2008;44(2):251-6.
Guo S, He X, Chen Q, Yang G, Yao K, Dong P, et al. The C-reactive protein/albumin ratio, a validated prognostic score, predicts outcome of surgical renal cell carcinoma patients. BMC Cancer. 2017;17(1):171.
Moher D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Ann Int Med. 2009;151(4):264-270.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. Haymarket - LD: Cochrane; 2017. 674 p.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol. 2010;17(6):1471-4.
Wells GA, Shea B, O'Connel D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2009 [Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014;72(1):39.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-58.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88.
Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002-d.
Hwang J-E, Kim H-N, Kim D-E, Choi H-J, Jung S-H, Shim H-J, et al. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer. 2011;11(1):489.
Hwang J-E, Kim H-N, Kim D-E, Shim H-J, Bae W-K, Hwang E-C, et al. First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status. Exp Ther Med. 2012;4(4):562-8.
Ishizuka M, Oyama Y, Abe A, Tago K, Tanaka G, Kubota K. Clinical significance of an inflammation-based prognostic system for gastric cancer patients with a preoperative normal serum level of carcinoembryonic antigen. Anticancer Res. 2014;34(12):7219-26.
Kubota T, Hiki N, Nunobe S, Kumagai K, Aikou S, Watanabe R, et al. Significance of the inflammation-based Glasgow prognostic score for short- and long-term outcomes after curative resection of gastric cancer. J Gastrointest Surg. 2012;16(11):2037-44.
Kunisaki C, Takahashi M, Ono HA, Oshima T, Takagawa R, Kimura J, et al. Inflammation-based prognostic score predicts survival in patients with advanced gastric cancer receiving biweekly docetaxel and s-1 combination chemotherapy. Oncology. 2012;83(4):183-91.
Li Q-Q, Lu Z-H, Yang L, Lu M, Zhang X-T, Li J, et al. Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy. Asian Pac J Cancer Prev. 2014;15(2):945-50.
Liu X, Sun X, Liu J, Kong P, Chen S, Zhan Y, et al. Preoperative C-Reactive Protein/Albumin Ratio Predicts Prognosis of Patients after Curative Resection for Gastric Cancer. Transl Oncol. 2015;8(4):339-45.
Liu X, Chen S, Liu J, Xu D, Li W, Zhan Y, et al. Impact of systemic inflammation on gastric cancer outcomes. PloS ONE. 2017;12(3):e0174085-e.
Melling N, Graning A, Tachezy M, Nentwich M, Reeh M, Uzunoglu FG, et al. Glasgow Prognostic Score may be a prognostic index for overall and perioperative survival in gastric cancer without perioperative treatment. Surgery. 2016;159(6):1548-56.
Namikawa T, Munekage E, Munekage M, Maeda H, Yatabe T, Kitagawa H, et al. Evaluation of Systemic Inflammatory Response Biomarkers in Patients Receiving Chemotherapy for Unresectable and Recurrent Advanced Gastric Cancer. Oncology. 2016;90(6):321-6.
Nozoe T, Iguchi T, Egashira A, Adachi E, Matsukuma A, Ezaki T. Significance of modified Glasgow prognostic score as a useful indicator for prognosis of patients with gastric carcinoma. Am J Surg. 2011;201(2):186-91.
Pan Q-X, Su Z-J, Zhang J-H, Wang C-R, Ke S-Y. A comparison of the prognostic value of preoperative inflammation-based scores and TNM stage in patients with gastric cancer. OncoTargets Ther. 2015;8:1375-85.
Sachlova M, Majek O, Tucek S. Prognostic value of scores based on malnutrition or systemic inflammatory response in patients with metastatic or recurrent gastric cancer. Nutr Cancer. 2014;66(8):1362-70.
Sun X, Wang J, Liu J, Chen S, Liu X. Albumin concentrations plus neutrophil lymphocyte ratios for predicting overall survival after curative resection for gastric cancer. OncoTargets Ther. 2016;9:4661-9.
Wang D-s, Ren C, Qiu M-Z, Luo H-Y, Wang Z-q, Zhang D-S, et al. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumour Biol. 2012;33:749-56.
Li M-x, Bi X-y, Li Z-y, Huang Z, Han Y, Zhou J-g, et al. Prognostic Role of Glasgow Prognostic Score in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Medicine. 2015;94(49):e2133-e.
Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187-93.
Polterauer S, Grimm C, Seebacher V, Rahhal J, Tempfer C, Reinthaller A, et al. The Inflammation-Based Glasgow Prognostic Score Predicts Survival in Patients With Cervical Cancer. Int J Gynecol Cancer. 2010;20(6):1052-7.
Murri AMA, Bartlett JMS, Canney PA, Doughty JC, Wilson C, McMillan DC. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer. 2006;94(2):227-30.
Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, et al. The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer. 2013;13(1):13:52.
Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW, McKay CJ. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology. 2006;6(5):450-3.
Jamieson NB, Mohamed M, Oien KA, Foulis AK, Dickson EJ, Imrie CW, et al. The relationship between tumor inflammatory cell infiltrate and outcome in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2012;19(11):3581-90.
Richards CH, Roxburgh CSD, MacMillan MT, Isswiasi S, Robertson EG, Guthrie GK, et al. The Relationships between Body Composition and the Systemic Inflammatory Response in Patients with Primary Operable Colorectal Cancer. PloS ONE. 2012;7(8):e41883.
Nazha B, Moussaly E, Zaarour M, Weerasinghe C, Azab B. Hypoalbuminemia in colorectal cancer prognosis: Nutritional marker or inflammatory surrogate? World J Gastrointest Surg. 2015;7(12):370-7.
Petrelli F, Barni S, Coinu A, Bertocchi P, Borgonovo K, Cabiddu M, et al. The Modified Glasgow Prognostic Score and Survival in Colorectal Cancer: A Pooled Analysis of the Literature. Rev Recent Clin Trials. 2015;10(2):135-41.
Lamb GWA, Aitchison M, Ramsey S, Housley SL, McMillan DC. Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems. Br J Cancer. 2011;106(2):279-83.
Ramsey S, Lamb GWA, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer. 2007;109(2):205-12.
Gao Y, Huang D. The value of the systematic inflammation-based Glasgow Prognostic Score in patients with gastric cancer: a literature review. J Cancer Res Ther. 2014;10(4):799-804.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2021 Higino Felipe Figueiredo, Rosane Dias Da Rosa, Luciana Botinelly Mendonça Fujimoto, Renata Motoki Amorim Pereira, Fernando Luiz Westphal, Gerson Suguiyama Nakajima
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
